Alnylam, Sanofi Restructure RNAi Rare-Disease Alliance -- Update
08 January 2018 - 08:37AM
Dow Jones News
By Colin Kellaher
Alnylam Pharmaceuticals Inc. (ALNY) and Sanofi (SNY) on Sunday
said they agreed to restructure their RNAi therapeutics alliance to
streamline and optimize development of certain products for the
treatment of rare genetic diseases.
As part of the restructuring, Cambridge, Mass.,
biopharmaceutical company Alnylam will obtain global development
and commercialization rights to its investigational RNAi
therapeutics programs for the treatment of ATTR amyloidosis,
including patisiran and ALN-TTRsc02, while Sanofi obtains global
development and commercialization rights to fitusiran, an
investigational therapeutic in development for the treatment of
hemophilia A and B.
France's Sanofi will receive royalties based on net sales of the
ATTR amyloidosis products, and Alnylam will receive royalties based
on sales of fitusiran products.
The companies said terms of their 2014 agreement with respect to
other products under the alliance are unchanged.
Alnylam said it is preparing for the launch of patisiran in
mid-2018 in the U.S. and late 2018 in Europe. Patisiran is
currently under regulatory review for the treatment of hATTR
amyloidosis, an inherited, progressive disease caused by a genetic
mutation that can result in the formation of amyloid deposits in
the heart, nerves and gastrointestinal tract.
The company also said it expects to end 2017 with more than $1.7
billion in cash, cash equivalents, marketable securities and
restricted cash.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 07, 2018 16:22 ET (21:22 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2023 to Mar 2024